Psychedelic Drugs Could Create a $100 Billion Investment Opportunity
With psychedelic drugs showing promise with mental health issues, investors have just begun to push into a space that could be worth up to $100 billion, according to Tania Gonsalves, analyst for Canaccord Genuity Capital Markets, as quoted by Psychedlic Spotlight. She added, “the companies that will emerge as the winners will have deep pockets, patentable products and a well-thought-out reimbursement strategy. Helping, more cities are just beginning to decriminalize psychedelics, like psilocybin. For example, Denver, Oakland, and Santa Cruz have legalized the use of psilocybin. Oregon also became the first state to legalize psilocybin in a therapeutic setting. With excitement growing with psychedelics, some of the top companies to watch include
Share this article
Share this article
TORONTO, Dec. 14, 2020 /PRNewswire/ - N2 Logics Inc. in a joint venture with New Wave Holdings Ltd. – NEW WAVE HOLDINGS CORP. (the Company or New Wave ) (CSE: SPOR) (FWB: 0XM2) (OTC: TRMNF) an investment issuer that provides capital and support services, has announced that N2 Logics Inc. ( N2 ), an entity that New Wave owns a significant interest in, has acquired one of Europe s leading CBD and nutraceuticals online superstore distributing various health & wellness products
Daniel Fox, CEO New Wave Holdings comments, healthier and more natural plant based health and wellness products are continuing to grow in importance in today s society. Our goal is to distribute and provide consumers access to products that improve human functionality and performance. With N2 s leading ecommerce strategy, we expect continue to generate significant high margin online growth starting in Europe then quickly expanding into North America and the rest of